Cidara Therapeutics (CDTX) News Today $22.06 +0.04 (+0.18%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$21.70 -0.36 (-1.61%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $41.86 Consensus PT from AnalystsMay 30 at 2:38 AM | americanbankingnews.comCidara Therapeutics' (CDTX) Market Outperform Rating Reiterated at JMP SecuritiesMay 29 at 2:05 AM | americanbankingnews.comJMP Securities Reaffirms Market Outperform Rating for Cidara Therapeutics (NASDAQ:CDTX)JMP Securities restated a "market outperform" rating and set a $47.00 price objective on shares of Cidara Therapeutics in a research report on Tuesday.May 28 at 9:30 AM | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of "Buy" from AnalystsShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have been assigned an average rating of "Buy" from the nine research firms that are covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy ratinMay 28 at 1:31 AM | marketbeat.comRoyal Bank of Canada Increases Cidara Therapeutics (NASDAQ:CDTX) Price Target to $35.00May 26, 2025 | americanbankingnews.comCidara Therapeutics' (CDTX) Buy Rating Reiterated at Needham & Company LLCMay 26, 2025 | americanbankingnews.comCidara Therapeutics: All Stars Aligning In Favor Of CD388May 25, 2025 | seekingalpha.comRoyal Bank of Canada Boosts Cidara Therapeutics (NASDAQ:CDTX) Price Target to $35.00Royal Bank of Canada raised their price target on Cidara Therapeutics from $31.00 to $35.00 and gave the company an "outperform" rating in a report on Friday.May 25, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Cidara Therapeutics in a research note on Friday.May 25, 2025 | marketbeat.comRBC Capital Reaffirms Their Buy Rating on Cidara Therapeutics (CDTX)May 24, 2025 | theglobeandmail.comVR Adviser LLC Takes Position in Cidara Therapeutics, Inc. (NASDAQ:CDTX)VR Adviser LLC purchased a new stake in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 765,723 shares of the biotechnology company's stock,May 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Makes New Investment in Cidara Therapeutics, Inc. (NASDAQ:CDTX)OMERS ADMINISTRATION Corp bought a new position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,600 shares of the biotechnology companyMay 22, 2025 | marketbeat.comCidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025May 15, 2025 | globenewswire.comCidara Therapeutics to Participate in Two Upcoming Investor ConferencesMay 13, 2025 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Posts Quarterly Earnings Results, Beats Estimates By $3.79 EPSCidara Therapeutics (NASDAQ:CDTX - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($1.66) earnings per share for the quarter, topping the consensus estimate of ($5.45) by $3.79. Cidara Therapeutics had a negative return on equity of 69.64% and a negative net margin of 289.05%.May 12, 2025 | marketbeat.comStockNews.com Upgrades Cidara Therapeutics (NASDAQ:CDTX) to SellStockNews.com upgraded shares of Cidara Therapeutics to a "sell" rating in a research note on Saturday.May 12, 2025 | marketbeat.comCidara Therapeutics, Inc. (CDTX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comCidara Therapeutics Reports Data Cutoff for Phase 2b NAVIGATE Trial of CD388 with Top-Line Results Anticipated in June 2025May 10, 2025 | nasdaq.comCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deCidara Therapeutics price target raised to $35 from $33 at GuggenheimMay 9, 2025 | msn.comSchonfeld Strategic Advisors LLC Buys 30,057 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX)Schonfeld Strategic Advisors LLC raised its position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 154.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 49,557 shares of the biotechnMay 9, 2025 | marketbeat.comCidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Shares Acquired by BVF Inc. ILBVF Inc. IL increased its position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 55.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,092,796 shares of the biMay 6, 2025 | marketbeat.comAlethea Capital Management LLC Sells 65,597 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX)Alethea Capital Management LLC lowered its stake in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 82.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,311 shares of the biotechnMay 6, 2025 | marketbeat.comCidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu CandidateMay 5, 2025 | seekingalpha.com54,473 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Bought by Acuta Capital Partners LLCAcuta Capital Partners LLC purchased a new position in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 54,473 shares of the biotechnology company'sMay 4, 2025 | marketbeat.comBoothbay Fund Management LLC Makes New Investment in Cidara Therapeutics, Inc. (NASDAQ:CDTX)Boothbay Fund Management LLC purchased a new stake in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,601 shares of the biotechnology company's stock, valMay 4, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by BrokeragesShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have been given a consensus recommendation of "Buy" by the nine research firms that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two haveMay 4, 2025 | marketbeat.comRA Capital Management L.P. Purchases 389,716 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX)RA Capital Management L.P. increased its position in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 55.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,092,796 shares of the biotechnology company's stock aftMay 3, 2025 | marketbeat.comCidara Therapeutics (CDTX) to Release Earnings on ThursdayCidara Therapeutics (NASDAQ:CDTX) will be releasing its Q1 2025 earnings after the market closes on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-cidara-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comCidara Therapeutics appoints new CMO and SVPMay 2, 2025 | investing.comCidara Therapeutics (NASDAQ:CDTX) Given Market Outperform Rating at JMP SecuritiesJMP Securities reissued a "market outperform" rating and issued a $46.00 target price on shares of Cidara Therapeutics in a research note on Tuesday.May 1, 2025 | marketbeat.com1,005,901 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Bought by TCG Crossover Management LLCTCG Crossover Management LLC bought a new stake in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,005,901 shares of the biotechnology company's stock, valuMay 1, 2025 | marketbeat.comCidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical DevelopmentMay 1, 2025 | globenewswire.comCidara Therapeutics to Participate in The Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comAdage Capital Partners GP L.L.C. Increases Stock Holdings in Cidara Therapeutics, Inc. (NASDAQ:CDTX)Adage Capital Partners GP L.L.C. increased its position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 765.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 369,954 shares of the biotechnoApril 30, 2025 | marketbeat.comCidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025April 24, 2025 | globenewswire.comVivo Capital LLC Purchases Shares of 670,600 Cidara Therapeutics, Inc. (NASDAQ:CDTX)Vivo Capital LLC purchased a new position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 670,600 shares of the biotechnology companApril 23, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Upgraded to "Sell" at StockNews.comStockNews.com raised shares of Cidara Therapeutics to a "sell" rating in a research report on Wednesday.April 17, 2025 | marketbeat.comPhathom Pharmaceuticals Appoints Ted Schroeder to its Board of DirectorsApril 16, 2025 | globenewswire.comCidara Therapeutics' (CDTX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $35.00 target price on shares of Cidara Therapeutics in a research note on Thursday.April 12, 2025 | marketbeat.com24,938 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Bought by ADAR1 Capital Management LLCADAR1 Capital Management LLC bought a new position in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 24,938 shares of the biotechnology coApril 9, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Raised to Sell at StockNews.comStockNews.com upgraded Cidara Therapeutics to a "sell" rating in a report on Friday.April 6, 2025 | marketbeat.comShort Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Expands By 21.9%Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 289,900 shares, an increase of 21.9% from the February 28th total of 237,800 shares. Based on an average daily trading volume, of 122,300 shares, the days-to-cover ratio is currently 2.4 days. Approximately 4.2% of the company's stock are sold short.April 4, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Pass Above 50 Day Moving Average - Time to Sell?Cidara Therapeutics (NASDAQ:CDTX) Stock Price Crosses Above Fifty Day Moving Average - Here's What HappenedApril 3, 2025 | marketbeat.comCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)April 1, 2025 | globenewswire.comCidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comElicio Therapeutics appoints Preetam Shah as chief strategy, financial officerMarch 24, 2025 | markets.businessinsider.comCidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and ResponseMarch 19, 2025 | globenewswire.comCidara Therapeutics to present on CD388 at ICAR 2025March 19, 2025 | markets.businessinsider.com Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CDTX Media Mentions By Week CDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDTX News Sentiment▼0.660.87▲Average Medical News Sentiment CDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDTX Articles This Week▼123▲CDTX Articles Average Week Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) News Today Ocular Therapeutix News Today Amphastar Pharmaceuticals News Today Aurinia Pharmaceuticals News Today Mineralys Therapeutics News Today Arcus Biosciences News Today Ardelyx News Today Intellia Therapeutics News Today Phibro Animal Health News Today Collegium Pharmaceutical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDTX) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDTX Stock Free CDTX Stock Alerts